Back to Search Start Over

Prevalence of Gastrointestinal Symptoms in Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Results of the Prospective Controlled Multinational GI-COVID-19 Study

Authors :
Marasco, G.
Cremon, C.
Barbaro, M. R.
Salvi, D.
Cacciari, G.
Kagramanova, A.
Bordin, D.
Drug, V.
Miftode, E.
Fusaroli, P.
Mohamed, S. Y.
Ricci, C.
Bellini, M.
Rahman, M. M.
Melcarne, L.
Santos, J.
Lobo, B.
Bor, S.
Yapali, S.
Akyol, D.
Sapmaz, F. P.
Urun, Y. Y.
Eskazan, T.
Celebi, A.
Kacmaz, H.
Ebik, B.
Binicier, H. C.
Bugdayci, M. S.
Yagci, M. B.
Pullukcu, H.
Kaya, B. Y.
Tureyen, A.
Hatemi, I.
Koc, E. S.
Sirin, G.
Caliskan, A. R.
Bengi, G.
Alis, E. E.
Lukic, S.
Trajkovska, M.
Hod, K.
Dumitrascu, D.
Pietrangelo, A.
Corradini, E.
Simren, M.
Sjolund, J.
Tornkvist, N.
Ghoshal, U. C.
Kolokolnikova, O.
Colecchia, A.
Serra, J.
Maconi, G.
De Giorgio, R.
Danese, S.
Portincasa, P.
Di Stefano, M.
Maggio, M.
Philippou, E.
Lee, Y. Y.
Venturi, A.
Borghi, C.
Zoli, M.
Gionchetti, P.
Viale, P.
Stanghellini, V.
Barbara, G.
Piacentini, A.
Shengelia, M.
Vechorko, V.
Cardamone, C.
Rosei, C. A.
Pancetti, A.
Rettura, F.
Pedrosa, M.
Campoli, C.
Mijac, D.
Korac, M.
Karic, U.
Markovic, A.
Najdeski, A.
Nikolova, D.
Dimzova, M.
Lior, O.
Shinhar, N.
Perelmutter, O.
Ringel, Y.
Sabo, C. M.
Chis, A.
Bonucchi, G.
Caio, G. P. I.
Ghirardi, C.
Marziani, B.
Rizzello, B.
Aguilar, A.
Capogreco, A.
Aghemo, A.
Di Paolo, D. M.
Marconi, G.
Di Sabatino, A.
Tagliaferri, S.
Naves, J. E.
Galli, A.
Dragoni, G.
Nedelcu, L.
Mauloni, P. A.
Del Vecchio, S.
Rotondo, L.
Capuani, F.
Montanari, D.
Palombo, F.
Paone, C.
Mastel, G.
Fontana, C.
Bellacosa, L.
Cogliandro, R. F.
Marasco, Giovanni
Cremon, Cesare
Barbaro, Maria Raffaella
Salvi, Daniele
Cacciari, Giulia
Kagramanova, Anna
Bordin, Dmitry
Drug, Vasile
Miftode, Edgidia
Fusaroli, Pietro
Mohamed, Salem Youssef
Ricci, Chiara
Bellini, Massimo
Rahman, M Masudur
Melcarne, Luigi
Santos, Javier
Lobo, Beatriz
Bor, Serhat
Yapali, Suna
Akyol, Deniz
Sapmaz, Ferdane Pirincci
Urun, Yonca Yilmaz
Eskazan, Tugce
Celebi, Altay
Kacmaz, Huseyin
Ebik, Berat
Binicier, Hatice Cilem
Bugdayci, Mehmet Sait
Yağcı, Munkhtsetseg Banzragch
Pullukcu, Husnu
Kaya, Berrin Yalınba
Tureyen, Ali
Hatemi, İbrahim
Koc, Elif Sitre
Sirin, Goktug
Calıskan, Ali Riza
Bengi, Goksel
Alıs, Esra Ergun
Lukic, Snezana
Trajkovska, Meri
Hod, Keren
Dumitrascu, Dan
Pietrangelo, Antonello
Corradini, Elena
Simren, Magnu
Sjolund, Jessica
Tornkvist, Navkiran
Ghoshal, Uday C
Kolokolnikova, Olga
Colecchia, Antonio
Serra, Jordi
Maconi, Giovanni
De Giorgio, Roberto
Danese, Silvio
Portincasa, Pietro
Di Stefano, Michele
Maggio, Marcello
Philippou, Elena
Lee, Yeong Yeh
Venturi, Alessandro
Borghi, Claudio
Zoli, Marco
Gionchetti, Paolo
Viale, Pierluigi
Stanghellini, Vincenzo
Barbara, Giovanni
Source :
American Journal of Gastroenterology, r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol, instname
Publication Year :
2022

Abstract

INTRODUCTION: Gastrointestinal (GI) symptoms in coronavirus-19 disease (COVID-19) have been reported with great variability and without standardization. In hospitalized patients, we aimed to evaluate the prevalence of GI symptoms, factors associated with their occurrence, and variation at 1 month. METHODS: The GI-COVID-19 is a prospective, multicenter, controlled study. Patients with and without COVID-19 diagnosis were recruited at hospital admission and asked for GI symptoms at admission and after 1 month, using the validated Gastrointestinal Symptom Rating Scale questionnaire. RESULTS: The study included 2036 hospitalized patients. A total of 871 patients (575 COVID+ and 296 COVID-) were included for the primary analysis. GI symptoms occurred more frequently in patients with COVID-19 (59.7%; 343/575 patients) than in the control group (43.2%; 128/296 patients) (P < 0.001). Patients with COVID-19 complained of higher presence or intensity of nausea, diarrhea, loose stools, and urgency as compared with controls. At a 1-month follow-up, a reduction in the presence or intensity of GI symptoms was found in COVID-19 patients with GI symptoms at hospital admission. Nausea remained increased over controls. Factors significantly associated with nausea persistence in COVID-19 were female sex, high body mass index, the presence of dyspnea, and increased C-reactive protein levels. DISCUSSION: The prevalence of GI symptoms in hospitalized patients with COVID-19 is higher than previously reported. Systemic and respiratory symptoms are often associated with GI complaints. Nausea may persist after the resolution of COVID-19 infection.<br />Fondazione Cassa di Risparmio in Bologna; Italian Ministry of Education, University and Research; Fondazione del Monte di Bologna e Ravenna [SC1-BHC-01-2019]; European Grant H2020, DISCOvERIE [SC1-BHC-01-2019]; Italian Ministry of Health [Ricerca Finalizzata GR-2018-12367062]<br />G.B. contribution to this research was permitted in part by funding from Fondazione Cassa di Risparmio in Bologna; the ItalianMinistry of Education, University and Research; and Fondazione del Monte di Bologna e Ravenna and European Grant H2020, DISCOvERIE, SC1-BHC-01-2019. M.R.B. is a recipient of a grant from the Italian Ministry of Health (Ricerca Finalizzata GR-2018-12367062). None of the funding organizations have had any role in the design and conduct of the study; in the collection, management, and analysis of the data; or in the preparation, review, and approval of the article.

Details

Language :
English
ISSN :
15720241
Database :
OpenAIRE
Journal :
American Journal of Gastroenterology, r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol, instname
Accession number :
edsair.doi.dedup.....b0e8a59b0a70f8f010ca6775024bfc84